W9. Vaccines
Session: Premeeting Workshop: The Vincent T. Andriole ID Board Review Course ($)
Tuesday, October 2, 2018: 2:10 PM
Room: W 2005-2020
Nicola P. Klein, MD, PhD, Kaiser Permanente Vaccine Study Center, Oakland, CA

Nicola Klein, MD, PhD is a board certified Pediatrician, Director of the Kaiser Permanente Vaccine Study Center since 2006 and a Research Scientist III (rank equivalent to Professor) at the Kaiser Permanente Northern California Division of Research. She received her medical degree and her doctorate in Biochemistry as part of the NIH-funded Medical Scientist Training Program at New York University School of Medicine, completed her residency in Pediatrics at the Lucile Salter Packard Children’s Hospital at Stanford University School of Medicine and a Center for Disease Control (CDC)-sponsored Clinical Immunization Safety Assessment (CISA) Network Vaccine Safety Fellowship at Stanford. Her research has focused on vaccine safety and effectiveness, genetics of vaccine responses, vaccine safety among special populations and the epidemiology of vaccine preventable diseases. She is principal investigator (PI) for the CDC-sponsored Vaccine Safety Datalink Project and CISA Network and has led many vaccine safety studies, including describing the risk for febrile seizures following the combined measles-mumps-rubella-varicella vaccine separately among 1-2 year old and among 4-6 year olds, an FDA-sponsored case-control genome wide association study examining genes associated with an increased risk of febrile seizures in children following measles-containing vaccines, and evaluating the safety of vaccine administered to preterm infants and children with inborn errors or metabolism. She is also currently conducting a CISA study assessing the safety of simultaneous versus sequential vaccination in toddlers and leading a NVPO-sponsored study identifying genetic, immunologic and clinical factors predisposing children to fever after measles-containing vaccines. She is also PI on numerous vaccine clinical trials enrolling infants, children, adolescents and adults, as well as many recent observational studies investigating the effectiveness of acellular pertussis vaccines during pertussis outbreaks in California. She is currently investigating the effectiveness of the 13-valent pneumococcal vaccine in adults and waning effectiveness of influenza vaccines.


Disclosures:

N. P. Klein, Sanofi Pasteur: Investigator , Research grant . Merck: Investigator , Research grant . GSK: Investigator , Research grant . Pfizer: Investigator , Research support . Protein Science: Investigator , Research grant . MedImmune: Investigator , Research grant . Dynavax: Research Contractor , Grant recipient .

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.